Abstract: The invention provides methods and compositions for determining the identity of CRACM homologs underlying Icrac activity in cells.

Abstract: The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7.

Abstract: The invention relates to methods useful in identifying candidate agents that modulate insulin secretion from an insulin secreting cell, where such molecules modulate TRPM4 activity and expression in the insulin secreting cell.

Abstract: The present invention provides high throughput assays for TRPM7 activity. The present invention encompasses methods and compositions for screening a sample for inhibitors of TRPM7, including methods and compositions for competitive high throughput assays.

Abstract: The present invention provides assays and methods for determining levels of STIM2 activity, thus providing tools for the characterization and study of the regulation of intracellular calcium levels.

Abstract: The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7.

Abstract: The invention provides methods and compositions for determining the identity of CRACM homologs underlying Icrac activity in cells.

Abstract: The present invention provides assays and methods for determining levels of STIM2 activity, thus providing tools for the characterization and study of the regulation of intracellular calcium levels.

Abstract: The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein contain TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein.

Abstract: The invention relates to use of a calcium release activated Ca+2 (CRAC) channel (CRACM) such as CRACM1 and CRACM2 to identify bioactive agents which can modulate store operated calcium entry and CRAC channel activity. The invention further relates to the use of recombinant nucleic acids that encode CRACM. One aspect of the invention includes methods of determining binding of candidate bioactive agents to a CRACM polypeptide and for determining modulation of CRACM polypeptide activity as it affects CRAC channel permeability. The invention further relates to methods and compositions modulating the cellular expression of the nucleic acids that encode CRACM.

Abstract: The invention relates to methods useful in identifying candidate agents that modulate insulin secretion from an insulin secreting cell, where such molecules modulate TRPM4 activity and expression in the insulin secreting cell.

Abstract: The present invention relates to the identification and isolation of a novel family of ADP ribose (“ADPR) regulated calcium transmembrane channel polypeptides designated herein as “LTRPC2” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides open in response to concentrations of cytoplasmic ADPR in the micromolar range, exhibit enhanced activity in the presence of high intracellular levels of calcium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC2 for binding, and the methods for modulating LTRPC2 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC2.

Abstract: The invention relates to a method for modulating Ca2+-release-activated Ca2+ channels (CRAC) in a cell by administering to the cell a compound of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein.

Abstract: The present invention relates to the identification and isolation of a novel family of ADP ribose (“ADPR) regulated calcium transmembrane channel polypeptides designated herein as “LTRPC2” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides open in response to concentrations of cytoplasmic ADPR in the micromolar range, exhibit enhanced activity in the presence of high intracellular levels of calcium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC2 for binding, and the methods for modulating LTRPC2 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC2.